A Phase 2/3 interventional study of 5% Lidocaine patch and Placebo in Herpes Zoster Pain, sponsored by Mundipharma (China) Pharmaceutical Co. Ltd. Completed at 21 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-11-14.
Sponsored by Mundipharma (China) Pharmaceutical Co. Ltd (part of Mundipharma) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.
Among the 51 studies in Herpes Zoster with a site in China, this one is the 26th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2014, is the only one in phase 2/3, and was the 3rd registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 40+ · Healthy volunteers
Jiangsu Province Centers for Disease Control and Prevention · Sites in China
Ages 40+ · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 40+ · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 7 · Phase 4 6
First in 2011; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 243 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 519 across the 45 interventional studies, 187 across the 6 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma (China) Pharmaceutical Co. Ltd, one of the names counted as Mundipharma. Under that name alone:
Mundipharma (China) Pharmaceutical Co. Ltd is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
Mundipharma has 1 study filed under Herpes Zoster — fewer than ten, so there is no comparison to draw.
10 of the studies in Herpes Zoster with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06851832Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older | 2026-11-28 |
| NCT07099157Peking University Third HospitalEfficacy and Safety of Brivudine in the Treatment of Herpes Zoster | 2026-12-31 |
| NCT07361796Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster | 2027-09-30 |
| NCT07378046Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster | 2027-09-30 |
| NCT07378059Beijing Tiantan HospitalThe Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster | 2027-09-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 51 studies in Herpes Zoster with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of 5% lidocaine patch, following placebo or active patch applications in placebo insensitive subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active arm with administration of active 5% Lidocaine patch
Drug: 5% Lidocaine patch
Placebo arm with administration of placebo patch
Drug: Placebo
5% Lidocaine patch to be placed on the site of pain
Also known as: Lignopad
Placebo patch to be placed on the site of pain
Change of VAS score
Mean change in the mean pain VAS score
Time frame: over 24 hour from baseline to the post-treatment over time during double-blind period
Ran from Nov 2014 to primary completion in Dec 2015, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidoderm
Mundipharma (China) Pharmaceutical Co. Ltd →